SUPPLEMENTARY INFORMATION

mTOR coordinates transcriptional programs and mitochondrial metabolism of activated ${\rm T}_{\rm reg}$ subsets to protect tissue homeostasis

Chapman et al.



Supplementary Fig. 1. Foxp3^{Cre}-mediated deletion of Mtor in T_{req} cells leads to altered cytokine production and GC responses. a Deletion efficiency of Mtor in Trea cells as assessed by qPCR. b Quantification of IL-13- and IL-10-producing CD4⁺Foxp3⁻ T cells in *Foxp3^{Cre}Mtor*^{+/+ or +/fl} or *Foxp3^{Cre}Mtor*^{fl/fl} mice. **c** Quantification of the fold change of IFN-γ-, IL-4-, IL-13-, IL-10-, and IL-17A-producing CD4⁺Foxp3⁻ T cells in the spleen of Foxp3^{Cre}Mtor^{fl/fl} mice compared to Foxp3^{Cre}Mtor^{+/+} or ^{+/fl} mice. d Quantification of IL-4-, IL-17A-, and IFN-γ-producing CD4⁺Foxp3⁺ T_{reg} cells in Foxp3^{Cre}Mtor^{+/+ or +/fl} and Foxp3^{Cre}Mtor^{fl/fl} mice. e Representative immunohistochemistry of PNA⁺ cells, B220⁺ B cells, and CD3⁺ T cells in the mesenteric lymph nodes of Foxp3^{Cre}Mtor^{+/+} or ^{+/fl} and Foxp3^{Cre}Mtor^{fl/fl} mice. The boxed regions in PNA (10×) are shown at higher power in PNA (20×). f Quantification of the fold change of GC B cells and T_{FH} cells in the spleen of *Foxp3*^{Cre}*Rptor*^{+/+ or +/fl} and *Foxp3*^{Cre}*Rptor*^{fl/fl} mice. g, h Analysis of II4 (g) and II21 (h) expression in CD4+Foxp3-YFP-CD44hiCXCR5-PD-1- non-T_{FH} cells and CD4⁺Foxp3-YFP⁻CD44^{hi}CXCR5⁺PD-1⁺ T_{FH} cells isolated from the spleen of *Foxp3^{Cre}Mtor*^{+/+ or +/fl} or Foxp3^{Cre}Mtor^{fl/fl} mice. Error bars show mean \pm s.e.m. **P* < 0.05; ***P* < 0.01; ****P* < 0.001; ns, not significant; unpaired, two-tailed Student's t-test. Data are representative of three biological replicates (e) or are guantified from four (a), five (b, c, IL-10⁺ cells), or six or eight (b, c, IL-13⁺ cells in Foxp3^{Cre}Mtor^{+/+ or +/fl} or Foxp3^{Cre}Mtor^{fl/fl} mice, respectively), five (d, f), or three (g, h) biological replicates, compiled from two (a, f), five (b, IL-10⁺ cells; d), six (b, IL-13⁺ cells), twelve (c, IL-17A⁺ cells), fourteen (c, IFN- γ^+ and IL-4⁺ cells), or one (g, h) independent experiments.



Supplementary Fig. 2. T_H2 responses are elevated in the lung and skin of $Foxp3^{Cre}Mtor^{fl/fl}$ mice. **a** Quantification of the fold change of IFN- γ -, IL-4-, IL-13-, and IL-17A-producing CD4⁺Foxp3⁻ T cells in the lung of $Foxp3^{Cre}Mtor^{fl/fl}$ mice compared to $Foxp3^{Cre}Mtor^{+/+}$ or $^{+/fl}$ mice. **b** Representative images of major basic protein (MBP) staining for eosinophils in the skin of $Foxp3^{Cre}Mtor^{+/fl}$ and $Foxp3^{Cre}Mtor^{fl/fl}$ mice. **c** Representative images for M2 macrophages in the skin of $Foxp3^{Cre}Mtor^{+/fl}$ or $Foxp3^{Cre}Mtor^{+/fl}$ mice by CD163 and Ym1 staining. **d** Representative images for neutrophils, as indicated by inducible nitric oxide synthease 2 (iNOS2) staining, in the skin of $Foxp3^{Cre}Mtor^{+/fl}$ and $Foxp3^{Cre}Mtor^{fl/fl}$ mice. Error bars show mean \pm s.e.m. $^*P < 0.05$; ns, not significant; unpaired, two-tailed Student's *t*-test. Data are representative of three biological replicates per group (**b**–**d**) or are quantified from eight (**a**) biological replicates per group, compiled from four independent experiments (**a**).



Supplementary Fig. 3. mTOR supports activated T_{reg} cell expansion through a survival-independent mechanism. a Quantification of frequencies and cell numbers of mTOR-deficient CD4+Foxp3-YFP+CD44^{lo}CD62L^{hi} cT_{req} cells and CD4+Foxp3-YFP+CD44^{hi}CD62L^{lo} eT_{req} cells in mixed bone marrow chimeras. b Quantification of Raptor-deficient CD4+Foxp3-YFP+CD44^{lo}CD62L^{hi} cT_{reg} cells and CD4+Foxp3-YFP+CD44^{hi}CD62L^{lo} eT_{rea} cells in mixed bone marrow chimeras. c Quantification of the number of KLRG1+ T_{reg} cells in the spleen of Foxp3^{Cre/+}Mtor^{+/+ or +/fl} and Foxp3^{Cre/+}Mtor^{fl/fl} mosaic mice. d Quantification of CD25, ICOS, CTLA4, and Foxp3 expression in T_{req} cells in the spleen and peripheral lymph nodes (pLN) from Foxp3^{Cre/+}Mtor^{+/+ or +/fl} and Foxp3^{Cre/+}Mtor^{fl/fl} mosaic mice. e Quantification of the number of T_{FR} cells (CD4+Foxp3-YFP+CXCR5+PD-1+ T cells) in Foxp3^{Cre/+}Mtor^{+/+ or +/fl} and Foxp3^{Cre/+}Mtor^{fl/fl} mosaic mice. f cT_{reg} cells were activated in vitro for 16 h with anti-CD3 and anti-CD28 antibodies in the presence of IL-2. 7AAD staining was used to distinguish between live (7AAD-) and dead (7AAD+) cells. g Quantification of the frequencies and numbers of Foxp3-YFP⁺ T_{req} cells in the spleen and pLN of Foxp3^{Cre/DTR}Mtor^{+/+ or +/fl} or Foxp3^{Cre/DTR}Mtor^{fl/fl} mosaic mice following diphtheria toxin (DT) treatment. Error bars show mean ± s.e.m. * P < 0.05; ** P < 0.01; *** P < 0.001; ns, not significant; unpaired, two-tailed Student's t-test. Data are representative of two independent experiments (f) or are quantified from twelve or thirteen (a, CD45.2+Foxp3^{Cre}Mtor^{+/+} or +/fl chimera and CD45.2+Foxp3^{Cre}Mtor^{fl/fl} chimera, respectively), five or seven (**b**, CD45.2+Foxp3^{Cre}Rptor^{+/+} or +/fl chimera and CD45.2+Foxp3^{Cre}Rptor^{fl/fl} chimera, respectively), eight (c; d, CD25, CTLA4, and Foxp3), nine (d, ICOS), six (e), or three or four (g, as indicated) biological replicates, compiled from seven (a), four (b; c; d, CD25, CTLA4, and Foxp3), five (d, ICOS), three (e), or two (g) independent experiments. Numbers indicate percentage of cells in gates.





Supplementary Fig. 4. Characterization of mitochondrial metabolism in T_{reg} cells. **a** GSEA identified Hallmark pathways enriched in cT_{reg} cells activated for 20 h compared to unstimulated controls. **b** Metabolomics and metabolite set enriched analysis (MSEA) were used to identify various KEGG pathways upregulated in activated T_{reg} cells vs. unstimulated T_{reg} cells.



Supplementary Fig. 5. Characterization of T_{reg} and B cell populations in *Foxp3*^{Cre}*Tfam*^{fl/fl} mice and model for mTOR-dependent coordination of IRF4 and mitochondrial metabolism in programming T_{reg} cell function. **a** Quantification of IL-4-, IL-17A-, and IFN-γ-producing CD4⁺Foxp3⁺ T_{reg} cells in *Foxp3*^{Cre}*Tfam*^{+/+ or +/fl} and *Foxp3*^{Cre}*Tfam*^{fl/fl} mice. **b** Quantification of the numbers of B220⁺ B cells in the spleen of *Foxp3*^{Cre}*Tfam*^{+/+ or +/fl} and *Foxp3*^{Cre}*Tfam*^{fl/fl} mice. **c** Quantification of CD25 and Foxp3 expression in T_{reg} cells from mixed bone marrow chimeras. Error bars show mean ± s.e.m. ** *P* < 0.01; ns, not significant; unpaired, two-tailed Student's *t*-test. Data are quantified from six (**a**, IL-4⁺ cells), nine (**a**, IL-17A⁺ and IFN-γ⁺ cells), ten (**b**), or nine or ten (**c**, CD45.2⁺*Foxp3*^{Cre}*Tfam*^{+/+} chimeras and CD45.2⁺*Foxp3*^{Cre}*Tfam*^{+/fl} chimeras, respectively) biological replicates, compiled from six (**a**, IL-4⁺ cells), nine (**a**, IL-17A⁺ and IFN-γ⁺ cells), seven (**b**), or four (**c**) independent experiments. **d** In the periphery, TCR, co-stimulatory, IL-2, and inflammatory signals activate mTOR function in resting T_{reg} cells to promote IRF4 expression and mitochondrial metabolism. These pathways coordinately control T_{reg} cell activation and homeostasis. In turn, activated T_{reg} cells maintain peripheral T cell tolerance and tissue homeostasis.

Supplementary Table 1. GSEA of $cT_{\rm reg}$ activated with mTOR inhibitors vs. DMSO control for 20 h

| | Torin 1 20 h vs. DMSO 20 h | | | PP242 20 h vs. DMSO 20 h | | |
|------------------------------------|----------------------------|-----------|-----------|--------------------------|-----------|-----------|
| NAME | NES | NOM p-val | FDR q-val | NES | NOM p-val | FDR q-val |
| HALLMARK_E2F_TARGETS | -3.39 | < 0.001 | < 0.001 | -3.31 | < 0.001 | < 0.001 |
| HALLMARK_G2M_CHECKPOINT | -3.27 | < 0.001 | < 0.001 | -3.04 | < 0.001 | < 0.001 |
| HALLMARK_MYC_TARGETS_V1 | -3.16 | < 0.001 | < 0.001 | -3.08 | < 0.001 | < 0.001 |
| HALLMARK_MTORC1_SIGNALING | -2.89 | < 0.001 | < 0.001 | -2.78 | < 0.001 | < 0.001 |
| HALLMARK_OXIDATIVE_PHOSPHORYLATION | -2.79 | < 0.001 | < 0.001 | -2.70 | < 0.001 | < 0.001 |
| HALLMARK_MYC_TARGETS_V2 | -2.66 | < 0.001 | < 0.001 | -2.87 | < 0.001 | < 0.001 |
| HALLMARK_MITOTIC_SPINDLE | -2.21 | < 0.001 | < 0.001 | -2.16 | < 0.001 | 1.56E-04 |
| HALLMARK_UNFOLDED_PROTEIN_RESPONSE | -2.20 | < 0.001 | < 0.001 | -1.82 | < 0.001 | 4.95E-04 |
| HALLMARK_DNA_REPAIR | -2.12 | < 0.001 | < 0.001 | -2.17 | < 0.001 | 1.79E-04 |
| HALLMARK_INTERFERON_GAMMA_RESPONSE | -1.95 | < 0.001 | 1.32E-04 | -1.63 | < 0.001 | 6.90E-03 |
| HALLMARK_FATTY_ACID_METABOLISM | -1.84 | < 0.001 | 6.82E-04 | -2.05 | < 0.001 | 1.25E-04 |
| HALLMARK_GLYCOLYSIS | -1.81 | < 0.001 | 9.61E-04 | -1.97 | < 0.001 | 1.14E-04 |
| HALLMARK_ESTROGEN_RESPONSE_LATE | -1.79 | < 0.001 | 1.13E-03 | -1.75 | < 0.001 | 1.29E-03 |
| HALLMARK_ADIPOGENESIS | -1.75 | < 0.001 | 1.88E-03 | -1.64 | < 0.001 | 6.13E-03 |
| HALLMARK_UV_RESPONSE_UP | -1.63 | < 0.001 | 7.60E-03 | -1.71 | < 0.001 | 2.24E-03 |
| HALLMARK_CHOLESTEROL_HOMEOSTASIS | -1.62 | 1.32E-02 | 8.21E-03 | -2.06 | < 0.001 | 1.39E-04 |
| HALLMARK_SPERMATOGENESIS | -1.58 | < 0.001 | 1.28E-02 | -1.62 | < 0.001 | 6.74E-03 |
| HALLMARK_XENOBIOTIC_METABOLISM | -1.53 | < 0.001 | 1.75E-02 | -1.48 | 2.99E-03 | 2.18E-02 |
| HALLMARK_ALLOGRAFT_REJECTION | -1.51 | 5.21E-03 | 2.05E-02 | -1.58 | < 0.001 | 9.49E-03 |
| HALLMARK_PI3K_AKT_MTOR_SIGNALING | -1.41 | 2.40E-02 | 4.64E-02 | -1.40 | 3.48E-02 | 4.19E-02 |